Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMITID vs AVENTYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Irritable bowel syndrome,Enuresis
Major depressive disorder (endogenous depression)
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite nortriptyline.
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP2D6, CYP1A2, CYP2C19) via hydroxylation, N-demethylation, and N-oxidation; active metabolite: 10-hydroxynortriptyline. Metabolites are conjugated and excreted in urine.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
90-95% bound primarily to albumin and α1-acid glycoprotein.
90-95% bound primarily to albumin.
3-5 L/kg; indicates extensive tissue distribution.
15-30 L/kg; indicates extensive tissue penetration.
Oral: 60-70%; Intravenous: 100%.
Oral: 30-60% due to first-pass metabolism.
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50%. GFR <15 m L/min: contraindicated or use with extreme caution, maximum 25 mg/day.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 50% of normal dose or every 12 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce dose by 75% with monitoring.
Not FDA-approved for use in children <12 years. For adolescent depression (off-label): start 25 mg/day, titrate up to 50–100 mg/day. Weight-based: 1–3 mg/kg/day, not to exceed 150 mg/day.
Children 6-12 years: 10-30 mg/day in divided doses; >12 years: 25-50 mg/day in divided doses, maximum 100 mg/day. Weight-based: 1-2 mg/kg/day.
Start at 10–25 mg orally at bedtime; increase by 10–25 mg every 3–7 days to effective dose, typically 50–75 mg/day. Maximum 100 mg/day due to increased risk of anticholinergic effects, sedation, and orthostatic hypotension.
Initial dose 10-25 mg/day in divided doses, titrate slowly to maximum 100 mg/day; use with caution due to anticholinergic effects.
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Nortriptyline is not approved for use in pediatric patients.
Clinical worsening and suicide risk,Serotonin syndrome,Cardiovascular effects (QT prolongation, arrhythmia),Anticholinergic effects,Seizures,Angle-closure glaucoma,Urinary retention,Hepatic impairment,Hyponatremia
Suicidality: Monitor for worsening depression and suicidal thoughts, especially in young adults.,Cardiotoxicity: Risk of QT prolongation, arrhythmias, and sudden death; use with caution in patients with cardiovascular disease.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Anticholinergic effects: Use caution in patients with prostatic hypertrophy, narrow-angle glaucoma, or urinary retention.,Seizures: May lower seizure threshold.,Electroconvulsive therapy (ECT): Avoid concomitant use.,Hepatic impairment: Use with caution; metabolism may be reduced.,Hyperthyroidism: May potentiate cardiac toxicity.
Hypersensitivity to amitriptyline,Concomitant use with MAOIs (within 14 days),Acute recovery phase after myocardial infarction,Concurrent use of cisapride or other QT-prolonging drugs
Hypersensitivity to nortriptyline or any component of the formulation.,Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.,Acute recovery phase after myocardial infarction.,Concomitant use with cisapride, due to risk of QT prolongation.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Tyramine-rich foods (aged cheese, cured meats, fermented products) should be limited due to risk of hypertensive crisis. Maintain adequate fluid intake to prevent constipation.
Avoid tyramine-rich foods (aged cheeses, cured meats, sauerkraut, soy products, tap beers) as concomitant use with MAOIs is contraindicated. However, nortriptyline itself has minimal tyramine interaction. Grapefruit juice may increase nortriptyline levels; avoid or limit intake. High-fiber foods may reduce absorption; take with a full glass of water.
First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, based on observational studies. Absolute risk is low. Second and third trimesters: Chronic use may lead to neonatal adaptation syndrome (irritability, respiratory distress) and anticholinergic effects (e.g., constipation, urinary retention). Late third trimester exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN).
First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (irritability, feeding disorders) and anticholinergic effects (ileus, tachycardia).
Amitriptyline and its active metabolite nortriptyline are excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5–1.5. Relative infant dose is low (estimated <2% of weight-adjusted maternal dose). No adverse effects reported in infants followed prospectively. The American Academy of Pediatrics considers amitriptyline compatible with breastfeeding. However, monitor infant for sedation, poor feeding, and growth.
Excreted in human milk; M/P ratio unknown. Limited data suggests low levels; use with caution, monitor infant for sedation and anticholinergic effects.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce serum drug concentrations. Therapeutic drug monitoring (if available) can guide dose adjustments; clinical response may require dose increases by 30–50% in the second and third trimesters. Avoid abrupt withdrawal; taper if discontinuing.
Increased hepatic metabolism in pregnancy may require dose adjustment; start at low end of dosing range, titrate based on response and tolerability.
Amitriptyline is a tricyclic antidepressant with strong anticholinergic effects; monitor for QT prolongation, especially in elderly or those with cardiac disease. Start low (10-25 mg at bedtime) and titrate slowly. Avoid in recent MI, narrow-angle glaucoma, and urinary retention. Use with caution in seizure disorders.
Aventyl (nortriptyline) is a secondary amine tricyclic antidepressant with less anticholinergic and sedative effects than tertiary amines like amitriptyline. It exhibits a narrow therapeutic window; therapeutic plasma levels are 50-150 ng/m L. Use with caution in patients with cardiovascular disease due to risk of QT prolongation. Avoid abrupt discontinuation to prevent withdrawal-like symptoms. Monitoring of plasma levels is recommended in elderly and those with hepatic impairment.
Take this medication at bedtime as it may cause drowsiness.,Avoid alcohol and other CNS depressants.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,May cause dry mouth, constipation, blurred vision; report severe side effects like fainting or irregular heartbeat.,Full therapeutic effect may take 2-4 weeks.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of serotonin syndrome (agitation, hallucinations, fever) or suicidal thoughts.,May take 2-4 weeks to see full therapeutic effect.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store at room temperature away from moisture and light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMITID vs AVENTYL, answered by our medical review team.
AMITID is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.. AVENTYL is a Tricyclic Antidepressant that works by Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMITID and AVENTYL depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMITID is: 75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.. The standard adult dose of AVENTYL is: Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMITID and AVENTYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMITID is classified as Category C. First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, . AVENTYL is classified as Category C. First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.